| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.0004 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0005 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0006 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0006 |
| mRNA | JW-480 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0006 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.2 | 0.0007 |
| mRNA | JW-7-52-1 | GDSC1000 | pan-cancer | AAC | -0.18 | 0.0008 |
| mRNA | Gemcitabine | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0008 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | -0.11 | 0.0008 |
| mRNA | PD-0332991 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0008 |